Gossamer Bio Inc (GOSS)
0.5614
+0.04
(+7.96%)
USD |
NASDAQ |
Jun 17, 15:22
Gossamer Bio Enterprise Value: 79.65M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 79.65M |
| June 13, 2024 | 78.90M |
| June 12, 2024 | 79.74M |
| June 11, 2024 | 77.48M |
| June 10, 2024 | 78.52M |
| June 07, 2024 | 86.07M |
| June 06, 2024 | 97.75M |
| June 05, 2024 | 91.64M |
| June 04, 2024 | 87.45M |
| June 03, 2024 | 93.33M |
| May 31, 2024 | 95.48M |
| May 30, 2024 | 92.99M |
| May 29, 2024 | 94.15M |
| May 28, 2024 | 96.50M |
| May 24, 2024 | 102.25M |
| May 23, 2024 | 106.07M |
| May 22, 2024 | 106.45M |
| May 21, 2024 | 113.58M |
| May 20, 2024 | 116.59M |
| May 17, 2024 | 119.01M |
| May 16, 2024 | 127.15M |
| May 15, 2024 | 129.91M |
| May 14, 2024 | 127.79M |
| May 13, 2024 | 124.89M |
| May 10, 2024 | 129.94M |
| Date | Value |
|---|---|
| May 09, 2024 | 130.68M |
| May 08, 2024 | 132.90M |
| May 07, 2024 | 127.49M |
| May 06, 2024 | 138.62M |
| May 03, 2024 | 129.42M |
| May 02, 2024 | 136.50M |
| May 01, 2024 | 122.06M |
| April 30, 2024 | 122.63M |
| April 29, 2024 | 119.53M |
| April 26, 2024 | 113.13M |
| April 25, 2024 | 113.58M |
| April 24, 2024 | 122.24M |
| April 23, 2024 | 128.87M |
| April 22, 2024 | 130.09M |
| April 19, 2024 | 139.32M |
| April 18, 2024 | 144.35M |
| April 17, 2024 | 147.51M |
| April 16, 2024 | 147.69M |
| April 15, 2024 | 156.13M |
| April 12, 2024 | 164.52M |
| April 11, 2024 | 180.88M |
| April 10, 2024 | 188.16M |
| April 09, 2024 | 188.23M |
| April 08, 2024 | 206.33M |
| April 05, 2024 | 195.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-9.462M
Minimum
Oct 24 2023
1.400B
Maximum
Aug 24 2022
472.74M
Average
447.26M
Median
Feb 11 2021
Enterprise Value Benchmarks
| Merck & Co Inc | 356.61B |
| NovaBay Pharmaceuticals Inc | 3.382M |
| Palatin Technologies Inc | 19.39M |
| iBio Inc | 30.46M |
| Theriva Biologics Inc | -10.87M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.93M |
| Total Expenses (Quarterly) | 41.96M |
| EPS Diluted (Quarterly) | -0.19 |
| Earnings Yield | -178.1% |